# Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis

Study · id `cardio:ct-nct01503021` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01503021](<https://clinicaltrials.gov/study/NCT01503021>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01503021

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 718 participants.

## Technical summary

Registry record NCT01503021. Randomized; triple masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2014-01 (actual). Results posted on 2015-04-21.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 718 participants (enrolled count; ClinicalTrials.gov record NCT01503021, source copy `cardio:ctgov-nct01503021-2016-10-25`, retrieved 2026-10-26)
- Start date: 2011-11 (registry gives no type) (ClinicalTrials.gov record NCT01503021, source copy `cardio:ctgov-nct01503021-2016-10-25`, retrieved 2026-10-26)
- Primary completion: 2014-01 (actual) (ClinicalTrials.gov record NCT01503021, source copy `cardio:ctgov-nct01503021-2016-10-25`, retrieved 2026-10-26)
- Completion: 2014-01 (actual) (ClinicalTrials.gov record NCT01503021, source copy `cardio:ctgov-nct01503021-2016-10-25`, retrieved 2026-10-26)
- Results first posted: 2015-04-21 (ClinicalTrials.gov record NCT01503021, source copy `cardio:ctgov-nct01503021-2016-10-25`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT01503021, source copy `cardio:ctgov-nct01503021-2016-10-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01503021-2016-10-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis
- Condition: End Stage Renal Disease
- Condition: Chronic Kidney Disease
- Intervention (Drug): SFP
- Intervention (Other): Placebo
- Lead sponsor: Rockwell Medical Technologies, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Rockwell Medical Technologies, Inc. (`cardio:org-rockwell-medical-technologies-inc`)

## Provenance

Content hash: 5171c7daf983d48215efe25fd08dece26610a6f1f8899ff7ff414b15dd67be1a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
